Atrium Therapeutics, Inc. (RNA) company profile
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)
Close on Nov 17, 2026Market cap $110.85MP/E –Yield –
About Atrium Therapeutics
Pharmaceutical Preparations, SIC 2834
Atrium Therapeutics, Inc. is listed on Nasdaq under the ticker RNA, in the SEC industry Pharmaceutical Preparations. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Atrium Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 3020 Callan Road 92121
- Phone
- (858) 401-7900
- Website
- atriumtherapeutics.com
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- RNA
- Exchange
- Nasdaq
- IPO date
- Feb 27, 2026
- Shares outstanding
- 17M, Aug 3, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2093101
- CUSIP
- 04965N104
- ISIN
- US04965N1046
- FIGI
- BBG01Z0T3959
- Share class FIGI
- BBG01Z0T3B63
- EIN
- 39-4639499
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kathleen P. Gallagher | See Remarks, Director | 119,729 |
| Husam Younis | Chief Scientific Officer | 41,441 |
| Steven George Hughes | Chief Medical Officer | 51,638 |
| Brendan R. Winslow | Chief Financial Officer | 36,859 |
| Stephanie Kenney | See Remarks | 33,085 |
| Rocio Martin Hoyos | Chief Strategy Officer | 38,340 |
| W. Michael Flanagan | Director | 31,974 |
| Sarah Boyce | Director | 138,668 |
| Carsten Boess | Director | 11,005 |
| Simona Skerjanec | Director | 5,902 |
| Troy Edward Wilson | Director | 11,731 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 10, 2025 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
See a number that looks wrong?